From Lundbeck to Buy Abide Therapeutics For $250M, Make SD Lab a US Hub:

Alan-Ezekowitz-Picture
Alan-Ezekowitz-Picture

Headshot of Alan Ezekowitz, CEO of Abide Therapeutics, used with permission